Adults: 200 mg as a single dose or 100-200 mg twice daily for 5-14 days depending on the severity of the infection.
Upper respiratory tract infections (pharyngitis and tonsillitis which are recurrent, chronic, or resistant to other antibacterials): 100 mg twice daily (200 mg twice daily in sinusitis).
Lower respiratory tract infections (including bronchitis and pneumonia): 100-200 mg twice daily.
Skin and soft tissue infections: 200 mg twice daily.
Uncomplicated urinary tract infections: 100 mg twice daily (200 mg twice daily in uncomplicated upper urinary tract infections).
Uncomplicated gonorrhoea: 200 mg as a single dose.
Children: The recommended dose is 4 mg/kg twice daily for 5-14 days according to the severity of the infection, or as follows:
15 days - 6 months: 4 mg/kg body weight every 12 hours.
6 months - 2 years: 40 mg every 12 hours.
3 - 8 years: 80 mg every 12 hours.
Over 9 years: 100 mg every 12 hours.
Typhoid fever: 8 mg/kg body weight every 12 hours.

Cefpodoxime is contraindicated in patients with a known allergy to Cefpodoxime Proxetil or to cephalosporin group of antibiotic or any inactive ingredient of the product.

In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of Cefpodoxime should be reduced because high and prolonged serum antibiotic concentration can occur in such individuals following usual doses. Cefpodoxime should be administered with caution to patients receiving concurrent treatment with potent diuretics.

Diarrhoea and rarely antibiotic-associated colitis, nausea and vomiting, abdominal discomfort, headache; allergic reactions including rashes, pruritus, urticaria, serum sickness-like reactions with rashes, fever and arthralgia, and anaphylaxis, erythemia multiform, toxic epidermal necrolysis reported; disturbances in liver enzymes, transient hepatitis and cholestatic jaundice; etc.

Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminium hydroxide) or H2 blockers reduce peak levels and the extent of absorption, though the rate of absorption is not altered by these concomitant medications. Oral anticholinergics delay peak plasma levels, but do not affect the extent of absorption. Probenecid: Probenecid inhibits the excretion of Cefpodoxime. Nephrotoxic drugs: Although nephrotoxicity has not been noted when Cefpodoxime was given alone, close monitoring of renal function is advised when Cefpodoxime is administered concomitantly with compounds of known nephrotoxic potential.

Use in Pregnancy: Pregnancy category B. This drug should be used during pregnancy only if clearly needed.
Use in Lactation: Cefpodoxime Proxetil is excreted in human milk. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Taxetil-200 Capsule: Each box contains 8's capsules in Alu-Alu blister pack.
Taxetil 50 ml Powder for Suspension: Each bottle contains powder for the reconstitution of 50 ml suspension.
Taxetil DS Powder for Suspension: Each bottle containing powder for the reconstitution of 50 ml suspension.